1. Profiling Cancer Cells by Cell-SELEX
One of the greatest advantages of cell-SELEX is the possibility to perform the selection against a specific cell type without the prior knowledge of protein targets present on its surface. In such a way, a panel of aptamers can be generated that specifically recognizes the surface signature of the target cells and, through it, can distinguish those cells from the cells chosen for the counter-selection. These aptamers are applied as useful bioreagents for active cancer targeting and, notably, can be used as bait for the identification of new protein targets, playing an important role in biomarker discovery (Figure 1).
Figure 1. Aptamer discovery and development process. The image shows the sequential steps from the generation of aptamers by SELEX to their preclinical development as cancer-targeted therapeutics, imaging agents for diagnostics and theranostic molecules. Briefly, cancer cell-specific aptamers are generated by cell-SELEX against a specific cell type, without the prior knowledge of the molecular target. High affinity ligands are identified by classical cloning and/or high-throughput sequencing and bioinformatic analysis. The best aptamer candidates are tested in vitro for their affinity and specificity, optimized to increase their binding efficacy and tested in vitro/in vivo as cancer-targeted agents. The best binding aptamers are used as bait to identify their cell-surface targets, thus leading to discovery of novel biomarkers.
Cell-SELEX has been applied to different tumor types, including highly aggressive and heterogeneous cancers that lack well-defined biomarkers for a targeted therapy, with the intent to discover new aptamers able to bind to surface proteins, which differ in expression level between healthy and unhealthy cells or among different cancer cell phenotypes.
The first group who realized the opportunity to dissect biological complex targets using SELEX technology was Morris and Jensen’s group in 1998. They used human red blood cell membrane preparations as a complex mixture of potential targets to select a set of cell-specific ssDNA aptamers with high affinity for different cell membrane proteins
[1].t was not long before there was an understanding that this approach could be also applied to decode the specific surface signature of different kinds of cancer cells.
Tan’s group applied the SELEX technology to living cells to explore membrane protein biomarkers. In their pioneering work, they screened a DNA library on cultured precursor T cell acute lymphoblastic leukemia (ALL) to generate a panel of aptamers specifically discriminating target cells from human Burkitt’s lymphoma cells, used in the counter-selection steps. In particular, five aptamers (sgc8, sgc3, sgd3, sgc4, and sgd2) were able to bind to target cells at high affinity, with K
D values ranging from 0.80 ± 0.09 nM (sgc8) to 26.6 ± 2.1 nM (sgc4), and other ALL cell lines, but not to cultured B cells and acute myeloid leukemia (AML) cells
[2]. In addition, these aptamers could discriminate different leukemia cells (T-ALL, B-ALL, AML) in clinical samples, thus detecting subtle molecular differences among individual samples from leukemia patients in the same category
[3]. Post-SELEX target identification, based on aptamer-mediated affinity purification and mass spectrometry, allowed the match of sgc8 aptamer with its target, the transmembrane receptor protein tyrosine kinase 7 (PTK7)
[4]. Subsequently, as discussed below, this aptamer was applied as a new therapeutic tool for haemato-oncological malignancies
[5]. By using a similar strategy, Tan’s group also identified the immunoglobin heavy mu chain as the target for TD05 aptamer, which was selected by using the Burkitt’s lymphoma cell line Ramos as the target
[6]. Both of these studies demonstrate that this two-step strategy, the development of high-quality aptamer probes and the identification of their target proteins, is a powerful approach for biomarker discovery.
Through the use of several protocols, essentially based on altering positive selection steps on the chosen target cells and counter-selection steps on off-target cells, several aptamers have been to date developed with binding to unknown but unique characteristic surface proteins of target cells. For instance, aptamers have been generated that are able to discriminate high-metastatic from low-metastatic cancer cells of different tumor types, including colorectal carcinoma
[7], breast cancer
[8][9][10], osteosarcoma
[11], prostate cancer
[12][13] hepatocellular carcinoma
[14][15][16] and colon cancer
[17][18]. The generation of the above aptamer probes specifically targeting metastatic cancer cells provides a significant tool for diagnosis and treatment of the metastatic disease. For one of them, the investigation has already progressed to the target identification. Indeed, the RNA Apt63 aptamer, generated by a cell-SELEX approach for differential binding to prostate cancer cell lines with high vs. low metastatic potential, when used for aptamer-based affinity purification combined with mass spectrometry, matched to the plasma membrane ATP synthase beta subunit (ecto-ATP5B). Testing of the aptamer in vitro, as well as in xenograft models and human samples, proved this protein is a new marker for predicting and treating metastatic breast and prostate cancers
[13]. Moreover, applied to cancer cells belonging to different tumor types (pancreatic cancer PANC-1 cells vs. hepatocarcinoma Huh7 cells) a blind cell-SELEX approach raised an aptamer able to regulate epithelial–mesenchymal transition (EMT) and inhibit metastasis in pancreatic cancer by binding to cell-surface vimentin, as revealed by post-SELEX liquid chromatography tandem mass spectrometry analyses
[19].
It is known that cancer stem cells (CSCs) represent a small fraction of cells within a tumor mass exhibiting self-renewal and tumor-initiating capabilities, which contribute to recurrence, metastasis and therapeutic resistance. Unfortunately, specific biomarkers for CSCs are lacking, thus it remains extremely hard to eradicate them by effective therapeutic strategies
[20]. Notably, differential cell-SELEX has been applied to identify new markers of CSCs. Some groups succeeded in generating aptamers able to differentiate glioma stem cells from differentiated cells
[21][22], highlighting the potential of aptamers to target a molecular signature of CSCs for therapeutic applications. Similarly, aptamers have been generated to bind stemness-enriched cells in colorectal
[23], pancreatic
[24] and prostate
[25] cancers. The identification of the molecular targets of these aptamers may reveal new CSC biomarkers.
Further, to address the issue of resistance to therapy, cell-SELEX has been applied to discriminate drug-resistant cancer cells from sensitive counterparts. Recently, by using vemurafenib-resistant melanoma cells as a target of the selection and sensitive cells in counter-selection steps, Li et al. identified an aptamer specifically binding to CD63 on the surface of cancer cells
[26], thus opening the possibility to interfere with the TIMP-1/CD63 interaction at the cell surface, which recently emerged as a driver of malignant progression in melanoma and other human cancers
[27]. Furthermore, by a SELEX approach using taxol-resistant colon cancer cells in the positive selection and parental cells in counter-selection steps, Zhang et al. identified a DNA aptamer binding to human TfR at affinity comparable to that of human Tf. Importantly, they proved the ability of the aptamer to cross the intestinal epithelium barrier through TfR-mediated transcytosis, indicating its potential as a carrier for active drug delivery
[28].
In addition, we applied the differential cell-SELEX approach to different tumors, including NSCLC
[29] and glioblastoma (GBM)
[30], to generate aptamers able to target, within the same tumor type, cells characterized by a phenotype more aggressive than that of the cells used in the counter-selection, in terms of resistance to chemotherapy and tumorigenicity. Combining different post-SELEX biochemical approaches, we were able to identify EGFR and platelet-derived growth factor receptor beta (PDGFRβ) as the molecular targets of CL4 and Gint4.T aptamers, respectively, with the first coming from the selection on NSCLC cells
[29] and the second from that on GBM cells
[30]. Both 2′-fluoro-pyrimidine (2′-F-Py) containing RNA aptamers were subsequently validated as ligands and inhibitors of their proper receptor targets, not only when applied to cancer cells used for their selection but also in different tumor types, thus contributing to insight on the oncogenic role of these two RTKs, depending on the specific tumor expressing them. For instance, the anti-EGFR CL4 aptamer exerts a strong apoptotic effect on human NSCLC
[29], blocks the invasiveness of GBM cells expressing either the EGFRwt or EGFRvIII mutant
[30][31] and prevents the EGFR/integrin αvβ3 interaction on the surface of TNBC cells with a mesenchymal stem-like phenotype, which we first found to be required for vasculogenic mimicry and tumor growth of aggressive and poorly differentiated TNBC subtype
[32][33].
Similarly, the Gint4.T aptamer acts as a neutralizing ligand for PDGFRβ in cell lines, primary cultures and xenografts models of GBM
[30]. Further, it has been applied as a highly effective tool for imaging and suppression of TNBC lung metastases, thus indicating PDGFRβ as a reliable biomarker of a subgroup of TNBCs with invasive and stemlike phenotype
[33][34]. More recently, Gint4.T has been proven to potentiate the efficacy of immunotherapy with anti-programmed death-ligand 1 (PD-L1) mAb in the inhibition of tumor growth and metastasis in a syngeneic TNBC mouse model
[35].
Moreover, several cell-SELEX protocols have been applied to cancer cell lines by using normal cells for the counter-selection with the aim to identify novel cancer biomarkers for improving early diagnosis and therapy. For instance, 2′-F-Py RNA aptamers were selected on two different pancreatic cancer cell lines able to bind target cells and discriminate them from normal pancreatic ductal cells. Interestingly, aptamer-based target pull-down experiments on cell membrane lysates, combined with a genome-wide microarray analysis in cells targeted or not by the aptamer, identified the oncofetal protein alkaline phosphatase placental-like 2 (ALPPL-2) as the target of one of the selected aptamers and attributed a novel function to this protein as promoter of pancreatic cancer cell growth and invasion
[36]. By a similar approach, four aptamers were identified that differentiate nasopharyngeal cancer cells from nonmalignant nasopharyngeal cells, the cell-surface receptor CD109 identified as the target of one of them
[37]. The overexpression of CD109 in many human cancers and its association with metastasis and chemoresistance makes it an attractive target for diagnosis and therapy
[38].
Moreover, in order to generate aptamers against tumor cells in more physiologically conditions, 3D cell-SELEX protocols have been applied to spheroids of prostate
[39] and breast
[40] cancer cells by using nontumor cells for the negative selection.